Senisca, an Exeter, UK-based biotechnology company developing RNA-based senotherapeutics to treat age-related disease, raised additional £3.7M in funding.
The round, which brought the total amount to £7.1M, saw participation from Emerging Longevity Ventures, QantX, the R42 Group, Trend Investment Group and Apex Ventures, and investment from new funds including Lifespan Vision Ventures.
The company intends to use the funds to support continued evolution and the preclinical development of its senotherapeutic programmes, that target the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.
Led by CEO Dr Sarah Cole, Senisca is a spinout from the University of Exeter that has developed proprietary technology that harnesses RNA biology to reprogram aged ‘senescent’ cells. The company has identified a novel and druggable component of the cellular senescence response, RNA splicing dysregulation, which can be specifically targeted in the context of multiple pharmacological and skin health indications. Its senotherapeutics specifically target the novel cellular pathway which causes cell reprogramming and positively impacts markers of disease modification in patient-derived models. In line with the rapid evolution of the company, R&D activities are focused on IND data generation.
FinSMEs
18/03/202